ETTX - エンタシス・セラピュ―ティクス (Entasis Therapeutics Holdings Inc.) エンタシス・セラピュ―ティクス

 ETTXのチャート


 ETTXの企業情報

symbol ETTx
会社名 Entasis Therapeutics Holdings Inc (エンタシス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   エンタシス・セラピュ―ティクスは米国のバイオ医薬品事業持株会社。子会社を通じ、多剤耐性グラム陰性菌感染症の治療薬の新規発見、開発および商業化に焦点をあて事業を行う。主に多剤耐性アシネトバクタ―感染症、淋病、複雑性尿路感染症などの治療薬の臨床試験を手掛ける。本社所在地はマサチュ―セッツ州ウォルサム。   Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.
本社所在地 35 Gatehouse Drive Waltham MA 02451 USA
代表者氏名
代表者役職名
電話番号
設立年月日 42064
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 34人
url www.entasistx.com
nasdaq_url https://www.nasdaq.com/symbol/ettx
adr_tso
EBITDA EBITDA ー
終値(lastsale) 8.31
時価総額(marketcap) 0
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 ETTXのテクニカル分析


 ETTXのニュース

   Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update  2020/11/05 21:05:00 GlobeNewswire
WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused…
   The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure  2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
   Precipio, AnPac Bio-Medical Science leads the gainers pack, Cardiff Oncology, Fulgent Genetics amongst major losers  2020/09/04 15:04:09 Seeking Alpha
Gainers: Precipio (NASDAQ:PRPO) +15%, AnPac Bio-Medical Science Co ANPC +15%, The Cooper Companies (NYSE:COO) +7%, Entasis Therapeutics Holdings (NASDAQ:ET
   SmileDirectClub rallies on CEO boosting stake, NanoViricides surged on announcement of provide COVID-19 drug update on September 3, Aptorum stumbles on 1H results, ADiTx Therapeutics traded under pressure on pricing follow-on public offering  2020/09/02 15:08:58 Seeking Alpha
Gainers: SmileDirectClub (NASDAQ:SDC) +23%, NanoViricides (NYSEMKT:NNVC) +17%, Entasis Therapeutics Holdings (NASDAQ:ETTX) +15%, Nano-X Imaging (NASDAQ:NNO
   Entasis Therapeutics Holdings Inc. (ETTX): Are Hedge Funds Right About This Stock?  2019/11/24 18:56:51 Yahoo Finance
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked
   Entasis Therapeutics Holdings Inc. (ETTX): Are Hedge Funds Right About This Stock?  2019/11/24 18:56:51 Yahoo Finance
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked
   Entasis Therapeutics CEO: 'Our Antibiotics Work Differently'  2019/07/29 18:50:08 Benzinga
Benzinga spoke with Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) CEO Manos Perros, Ph.D. for the latest news and updates in the company's pathogen-targeted antimicrobial pipeline. Benzinga: In late June, Entasis announced that David Meek was appointed as chairman of the board. With over 25 years' experience, and as the current CEO of Ipsen, what does the addition of Meek mean for the company? Perros: David brings extensive industry experience to our board and a strong commercial background across several therapeutic areas, but in particular in oncology and rare diseases, providing a valuable strategic perspective as we work to successfully develop and commercialize our innovative pathogen-targeted treatments. Meek is also the CEO of a multinational company and has deep experience in dealmaking. Interestingly, Meek’s specialty is not in infectious diseases; however, our antibiotics work differently from the way that typical antibiotics have been prescribed and commercialized in the past, so we are closer to a rare disease model.
   Entasis Therapeutics reports Q1 results  2019/05/14 11:44:24 Seeking Alpha
   New CCO at Entasis Therapeutics  2019/04/23 12:45:06 Seeking Alpha
   Entasis Therapeutics reports FY results  2019/03/29 11:33:04 Seeking Alpha
   Entasis Therapeutics Holdings Inc. (ETTX): Are Hedge Funds Right About This Stock?  2019/11/24 18:56:51 Yahoo Finance
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked
   Entasis Therapeutics CEO: 'Our Antibiotics Work Differently'  2019/07/29 18:50:08 Benzinga
Benzinga spoke with Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) CEO Manos Perros, Ph.D. for the latest news and updates in the company's pathogen-targeted antimicrobial pipeline. Benzinga: In late June, Entasis announced that David Meek was appointed as chairman of the board. With over 25 years' experience, and as the current CEO of Ipsen, what does the addition of Meek mean for the company? Perros: David brings extensive industry experience to our board and a strong commercial background across several therapeutic areas, but in particular in oncology and rare diseases, providing a valuable strategic perspective as we work to successfully develop and commercialize our innovative pathogen-targeted treatments. Meek is also the CEO of a multinational company and has deep experience in dealmaking. Interestingly, Meek’s specialty is not in infectious diseases; however, our antibiotics work differently from the way that typical antibiotics have been prescribed and commercialized in the past, so we are closer to a rare disease model.
   Entasis Therapeutics reports Q1 results  2019/05/14 11:44:24 Seeking Alpha
   New CCO at Entasis Therapeutics  2019/04/23 12:45:06 Seeking Alpha
   Entasis Therapeutics reports FY results  2019/03/29 11:33:04 Seeking Alpha

 関連キーワード  (― 米国株 エンタシス・セラピュ―ティクス ETTX Entasis Therapeutics Holdings Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)